The influence of N-desmethylclozapine and clozapine on recognition memory and BDNF expression in hippocampus

Brain Research Bulletin

Volumn 84, Issue 2, 2011, Pages 144-150

  Ertuĝrul, Aygün ^a   Özdemir, Hatice ^a   Vural, Atay ^a   Dalkara, Turgay ^a   Meltzer, Herbert Y ^b   Saka, Esen ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

Brain derived neurotrophic factor (BDNF); Clozapine; Memory; N desmethylclozapine (NDMC); Schizophrenia

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CLOZAPINE; DIZOCILPINE; NORCLOZAPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; HIPPOCAMPUS; LONG TERM MEMORY; NONHUMAN; PRIORITY JOURNAL; RAT; RECOGNITION; SCHIZOPHRENIA; SHORT TERM MEMORY; WESTERN BLOTTING;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; BRAIN-DERIVED NEUROTROPHIC FACTOR; CLOZAPINE; COGNITION; DIZOCILPINE MALEATE; EXCITATORY AMINO ACID ANTAGONISTS; HIPPOCAMPUS; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; RATS; RATS, WISTAR; RECOGNITION (PSYCHOLOGY);

EID: 79451473008     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2010.11.014     Document Type: Article

References (68)

1. Angelucci F., Mathe A.A., Aloe L. Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered after haloperidol and risperidone administration. J. Neurosci. Res. 2000, 60:783-794.
2. Angelucci F., Brene S., Mathe A.A. BDNF in schizophrenia, depression and corresponding animal models. Mol. Psychiatry 2005, 10:345-352.
3. Bai O., Chlan-Fourney J., Bowen R., Keegan D., Li X.M. Expression of BDNF m RNA in rat hippocampus after treatmnet with antipsychotic drugs. J. Neurosci. Res. 2003, 71:127-131.
4. Balu D.T., Hoshaw B.A., Malberg J.E., Rosenzweig-Lipson S., Schechter L.E., Lucki I. Differential regulation of central BDNF protein levels by antidepressant and non-antidepressant drug treatments. Brain Res. 2008, 1211:37-43.
5. Bertaina-Anglade V., Enjuanes E., Morillon D., Drieu la Rochelle C. The object recognition task in rats and mice: a simple and rapid model in safety pharmacology to detect amnesic properties of a new chemical entity. J. Pharmacol. Toxicol. Methods 2006, 54:99-105.
6. Bevins R.A., Besheer J. Object recognition in rats and mice: a one trial none-matching to sample learning task to study recognition memory. Nat. Protoc. 2006, 1:1306-1322.
7. Carvalho A.L., Caldeira M.V., Santos S.D., Duarte C.B. Role of the brain derived neurotrophic factor at glutamatergic synapses. Br. J. Pharmacol. 2008, 153:310-324.
8. Castren E., Berzaghi M.P., Lindholm D., Thoenen H. Differential effects of MK-801 on BDNF mRNA levels in different regions of the rat brain. Exp. Neurol. 1993, 122:244-252.
9. Chlan-Fourney J., Ashe P., Nylen K., Juorio A.V., Li X.M. Differential regulation of hippocampal BDNF mRNA by typical and atypical antipsychotic administration. Brain Res. 2002, 954:11-20.
10. Chung Y.C., Li Z., Dai J., Meltzer H.Y., Ichikawa J. Clozapine increases both acetylcholine and dopamine release in rat ventral hippocampus: role of 5-HT1A receptor agonism. Brain Res. 2004, 1023:54-63.
11. de Lima M.N., Laranja D.C., Bromberg E., Roesler R., Schroder N.A. Pre- or post-training administration of the NMDA receptor blocker MK-801 impairs object recognition memory in rats. Behav. Brain Res. 2005, 156:139-143.
12. Dere E., Huston J.P., De Souza Silva M.A. The pharmacology, neuroanatomy and neurogenetics of one-trial object recognition in rodents. Neurosci. Biobehav. Rev. 2007, 31:673-704.
13. Didriksen M., Kreilgaard M., Arnt J. Sertindole, in contrast to clozapine and olanzapine, does not disrupt water maze performance after acute or chronic treatment. Eur. J. Pharmacol. 2006, 542:108-115.
14. Drzyga L.R., Marcinowska A., Obuchowics E. Antiapoptotic and neurotrophic effects of antidepressants: a review of clinical and experimental studies. Brain Res. Bull. 2009, 79:248-257.
15. Durany N., Michel T., Zochling R., Boissl K.W., Cruz-Sanchez F.F., Riederer P., Thome J. Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr. Res. 2001, 52:79-86.
16. Ennaceur A., Delacour J. A novel one-trial test for neurobiological studies of memory in rats. 1. Behavioral data. Behav. Brain Res. 1988, 31:47-59.
17. Enomoto T., Ishibashi T., Tokuda K., Ishiyama T., Toma S., Ito A. Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats. Behav. Brain Res. 2008, 186:197-207.
18. French S.J., Humby T., Horner C.H., Sofroniew M.V., Rattray M. Hippocampal neurotrophin and trk receptor mRNA levels are altered by local administration of nicotine, carbachol and pilocarpine. Mol. Brain Res. 1999, 67:124-136.
19. Fumagalli F., Molteni R., Roceri M., Bedogni F., Santero R., Fossati C., Gennarelli M., Racagni G., Riva M.A. Effect of antipsychotic drugs on BDNF expression under reduced NMDA receptor activity. J. Neurosci. Res. 2003, 72:622-628.
20. Fumagalli F., Molteni R., Bedogni F., Gennarelli M., Perez J., Racagni G., Riva M.A. Quetiapine regulates FGF-2 and BDNF expression in the hippocampus of animals treated with MK-801. Neuroreport 2004, 15:2109-2112.
21. Grayson B., Idris N.F., Neill J.C. Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat. Behav. Brain Res. 2007, 184:31-38.
22. Grillo R.W., Ottoni G.L., Leke R., Souza D.O., Portela L.V., Lara D.R. Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics. J. Psychiat. Res. 2007, 41:31-35.
23. Gwag B.J., Spri{dotless}nger J.E. Activation of NMDA receptors increases brain-derived neurotrophic factor (Bdnf) messenger-rna expression in the hippocampal-formation. Neuroreport 1993, 5:125-128.
24. Hagger C., Buckley P., Kenny J.T., Friedman L., Ubogy D., Meltzer H.Y. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol. Psychiatry 1993, 34:702-712.
25. Hashimoto K., Fujita Y., Shimizu E., Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent sub-chronic administration of clozapine, but not haloperidol. Eur. J. Pharmacol. 2005, 519:114-117.
26. Homayoun H., Moghaddam B. Fine tuning of awake prefrontal cortex neurons by clozapine: comparison with haloperidol and N-desmethylclozapine. Biol. Psychiatry 2007, 61:679-685.
27. Ichikawa J., Ishii H., Bonaccorso S., Fowler W.L., O'Laughlin I.A., Meltzer H.Y. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J. Neurochem. 2001, 76:1521-1531.
28. Ichikawa J., Dai J., Meltzer H.Y. 5-HT1A and 5-HT2A receptors minimally contribute to clozapine induced acetylcholine release in rat medial prefrontal cortex. Brain Res. 2002, 939:34-42.
29. Idris N.F., Grayson B., Platford E., Neill J.C. The ability of antipsychotics to prevent a sub-chronic pcp-induced cognitive deficit in the novel object recognition task in the rat. Soc. Neurosci. Abstracts 2005, 67:15.
30. Jeon G.S., Park S., Lee K., Lee M., Chun B., Shin K. Valproate prevents MK-801 induced changes in brain-derived neurotrophic factor mRNA in the rat brain. Eur. J. Pharmacol. 2006, 545:142-146.
31. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 1988, 45:789-796.
32. J.T. Kantrowitz, D.C. Javitt, N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia? Brain Res. Bull., 2010, doi:10.1016/j.brainresbull.2010.04.006.
33. Karasawa J., Hashimoto K., Chaki S. D-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats. Behav. Brain Res. 2008, 186:78-83.
34. Keefe R.S., Bilder R.M., Davis S.M., Harvey P.D., Palmer B.W., Gold J.M., Meltzer H.Y., Green M.F., Capuano G., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Davis C.E., Hsiao J.K., Lieberman J.A., Investigators CATI.E. Neurocognitive Working Group. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch. Gen. Psychiatry 2007, 64:633-647.
35. Kesslak J.P., Chuang K.R., Berchtold N.C. Spatial learning is delayed and brain-derived neurotrophic factor mRNA expression inhibited by administration of MK-801 in rats. Neurosci. Lett. 2003, 353:95-98.
36. Knipper M., da Penha Berzaghi M., Blöchl A., Breer H., Thoenen H., Lindholm D. Positive feedback between acetylcholine and the neurotrophins nerve growth factor and brain-derived neurotrophic factor in the rat hippocampus. Eur. J. Neurosci. 1994, 6:668-671.
37. Li Z., Huang M., Ichikawa J., Dai J., Meltzer H.Y. N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors. Neuropsychopharmacology 2005, 30:1986-1995.
38. Linden A.M., Vaisanen J., Lakso M., Nawa H., Wong G., Castren E. Expression of neurotrophins BDNF and NT-3, and their receptors in rat brain after administration of antipsychotic and psychotrophic agents. J. Mol. Neurosci. 2000, 14:27-37.
39. Lindholm D., Castren E., Berzaghi M., Blochl A., Thoenen H. Activity-dependent and hormonal regulation of neurotrophin mRNA levels in the brain - implications for neuronal plasticity. J. Neurobiol. 1994, 25:1362-1372.
40. Lipska B.K., Khaing Z.Z., Weickert C.S., Weinberger D.R. BDNF mRNA expression in rat hippocampus and prefrontal cortex: effects of neonatal ventral hippocampal damage and antipschotic drugs. Eur. J. Neurosci. 2001, 14:135-144.
41. Martinowich K., Lu B. Interaction between BDNF and serotonin: role in mood disorders. Neuropsychopharmacology 2008, 33:73-83.
42. Matsuki H., Shirayama Y., Hashimoto K., Tanaka A., Minabe Y. Effects of age and gender on the expression of brain derived neurotrophic factor mRNA in rat retrosplenial cortex following administation of dizocilpine. Neuropsychopharmacology 2001, 25:258-266.
43. McEvoy J.P., Lieberman J.A., Stroup T.S., Davis S.M., Meltzer H.Y., Rosenheck R.A., Swartz M.S., Perkins D.O., Keefe R.S., Davis C.E., Severe J., Hsiao J.K. CATIE investigators, effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am. J. Psychiatry 2006, 163:600-610.
44. K. McFarland, R.W. Johnson, T. Son, L. Pounds, K.E. Vanover, S. Bradley, et al., N-desmethlyclozapine demonstrated pro-cognitive actions in experimental models, International Congress on Schizophrenia Research 2007, Colorado Springs, CO.
45. Meltzer H.Y., Matsubara S., Lee J.C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin-2 pKi values. J. Pharmacol. Exp. Ther. 1989, 251:238-246.
46. Meltzer H.Y., McGurk S.R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr. Bull. 1999, 25:233-255.
47. Pichat P., Bergis O.E., Terranova J.P., Urani A., Duarte C., Santucci V., Gueudet C., Voltz C., Steinberg R., Stemmelin J., Oury-Donat F., Avenet P., Griebel G., Scatton B., SSR180711 a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. Neuropsychopharmacology 2007, 32:17-34.
48. Rajji T.K., Uchida H., Ismail Z., Ng W., Mamo D.C., Remington G., Pollock B.G., Mulsant B.H. Clozapine and global cognition in schizophrenia. J. Clin. Psychopharmacol. 2010, 30:431-436.
49. Schiapparelli L., Simon A.M., Del Rio J., Frechilla D. Opposing effects of AMPA and 5 HT1A receptor blockade on passive avoidance and object recognition performance: correlation with AMPA receptor subunit expression in rat hippocampus. Neuropharmacology 2006, 50:897-907.
50. Schröder N., de Lima M.N., Quevedo J., Dal Pizzol F., Roesler R. Impairing effects of chronic haloperidol and clozapine treatment on recognition memory: possible relation to oxidative stres. Schizophr. Res. 2005, 73:377-378.
51. Semba J., Wakuta M., Suhara T. Different effects of chronic phencyclidine on brain-derived neurotrophic factor in neonatal and adult rat brains. Addict. Biol. 2006, 11:126-130.
52. Shoval G., Weizman A. The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia. Eur. Neuropsychopharmacol. 2005, 15:319-329.
53. Skarsfeldt T. Differential effect of antipsychotics on place navigation of rats in the Morris water maze. Psychopharmacology (Berl) 1996, 124:126-133.
54. Snigdha S., Horiguchi M., Huang M., Li Z., Shahid M., Neill J.C., Meltzer H.Y. Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist. J. Pharmacol. Exp. Ther. 2010, 332:622-631.
55. Siuciak J.A., Chapin D.S., McCarthy S.A., Guanowsky V., Brown J., Chiang P., Marala R., Patterson T., Seymour P.A., Swick A., Iredale P.A. CP-809, 101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity. Neuropharmacology 2007, 52:279-290.
56. Sur C., Mallorga P.J., Wittmann M., Jacopson M.A., Pascarella D., Williams J.B., Brandish P.E., Pettibone D.J., Scolnick E.M., Conn P.J. N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates NMDA receptor activity. PNAS 2003, 100:13674-13679.
57. Szekeres G., Juhasz A., Rimanoczy A., Keri S., Janka Z. The C270T polymorphism of the brain-derived neurotrophic factor gene is associated with schizophrenia. Schizophr. Res. 2003, 65:15-18.
58. Tan Y.L., Zhou D.F., Cao L.Y., Zou Y.Z., Zhang X.Y. Decreased BDNF in serum of patients with chronic schizophrenia on long-term treatment with antipsychotics. Neurosci. Lett. 2005, 382:27-32.
59. Thornton A.E., Van Snellenberg J.X., Sepehry A.A., Honer W. The impact of atypical antipsychotic medications on long-term memory dysfunction in schizophrenia spectrum disorder: a quantitative review. J. Psychopharmacol. 2006, 20:335-346.
60. Toyooka K., Asama K., Watanabe Y., Muratake T., Takahashi M., Someya T., Nawa H. Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Res. 2002, 110:249-257.
61. Vaidya V.A., Marek G.J., Aghajanian G.K., Duman R.S. 5-HT2A receptor-mediated regulation of brain derived neurotrophic factor mRNA in the hippocampus and the neocortex. J. Neurosci. 1997, 17:2785-2795.
62. Valvassori S.S., Stertz L., Andreazza A.C., Rosa M.I., Kapczinski F., Streck E.L., Quevedo J. Lack of effect of antipsychotics on BNDF and NGF levels in hippocampus of Wistar rats. Metab. Brain Dis. 2008, 23:213-219.
63. Weiner D.M., Meltzer H.Y., Veinbergs I., Donohue E.M., Spalding T.A., Smith T.T., Mohell N., Harvey S.C., Lameh J., Nash N., Vanover K.E., Olsson R., Jayathilake K., Lee M., Levey A.I., Hacksell U., Burstein E.S., Davis R.E., Brann M.R. The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology (Berl) 2004, 177:207-216.
64. Woodward N.D., Purdon S.E., Meltzer H.Y., Zald D.H. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int. J. Neuropsychopharmacol. 2005, 8:457-472.
65. Woodward N.D., Purdon S.E., Meltzer H.Y., Zald D.H. A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophr. Res. 2007, 89:211-224.
66. Xiu M.H., Hui L., Dang Y.F., Hou T.D., Zhang C.X., Zheng Y.L., da Chen C., Kosten T.R., Zhang X.Y. Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33:1508-1512.
67. Yamada K., Mizuno M., Nabeshima T. Role for brain derived neurotrophic factor in learning and memory. Life Sci. 2002, 70:735-744.
68. Young J.W., Powell S.B., Risbrough V., Marston H.M., Geyer M.A. Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol. Ther. 2009, 122:150-202.